Bluejay Diagnostics (NASDAQ:BJDX) Director Fred Zeidman Buys 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Fred Zeidman acquired 12,500 shares of the company’s stock in a transaction that occurred on Saturday, March 14th. The stock was bought at an average cost of $2.00 per share, with a total value of $25,000.00. Following the purchase, the director owned 12,500 shares in the company, valued at $25,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Bluejay Diagnostics Price Performance

Shares of NASDAQ:BJDX opened at $1.72 on Tuesday. The company has a market cap of $1.78 million, a price-to-earnings ratio of -0.15 and a beta of 0.72. The firm has a 50 day simple moving average of $1.90 and a 200 day simple moving average of $3.19. Bluejay Diagnostics, Inc. has a one year low of $1.63 and a one year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.